PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8690513-2	1996	The major circulating metabolite of IDA is idarubicinol (IDOL).	idarubicinol	43-55	myosin regulatory light chain interacting protein	Homo sapiens	57-61
12955471-12	2004	CONCLUSIONS: The pharmacokinetics of IDA and its main metabolite idarubicinol in CHOP-derived protocols were not different from data obtained with other combinations or monotherapy.	idarubicinol	65-77	DNA damage inducible transcript 3	Homo sapiens	81-85
14565163-2	2003	In previous reports, the alcohol metabolite of IDA, 4-demethoxydaunorubicinol (idarubicinol, or IDOL), had cytotoxic activity and the ability to penetrate the blood-brain barrier.	idarubicinol	79-91	myosin regulatory light chain interacting protein	Homo sapiens	96-100
11243404-8	2001	The plasma IDA and idarubicinol (ida-ol) area under the curve"s of patients treated with IDA 12 mg/m2 plus CsA were higher (P< 0.05) than in controls.	idarubicinol	19-31	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	107-110
11243404-8	2001	The plasma IDA and idarubicinol (ida-ol) area under the curve"s of patients treated with IDA 12 mg/m2 plus CsA were higher (P< 0.05) than in controls.	idarubicinol	33-39	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	107-110
11243404-9	2001	Cellular IDA concentrations were almost similar, but cellular ida-ol concentrations were significantly higher (P < 0.05) in the presence of CsA than in controls.	idarubicinol	62-68	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	143-146
11243404-11	2001	The modulating effect of CsA was mainly based on changes in plasma kinetics of IDA and ida-ol, although ida-ol cellular clearance was delayed in the presence of CsA.	idarubicinol	87-93	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	25-28
11243404-11	2001	The modulating effect of CsA was mainly based on changes in plasma kinetics of IDA and ida-ol, although ida-ol cellular clearance was delayed in the presence of CsA.	idarubicinol	104-110	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	161-164
10342576-8	1999	Altogether, study results in MDR1+ cells incubated with CsA 1500 ng/ml plus idarubicin+idarubicinol 100+20 ng/ml, that are peak levels achievable in vivo with an idarubicin dose > or = 12 mg/m2 plus cyclosporin A 16 mg/kg/d, were in the range of those obtained with standard-dose daunorubicin in MDR1- cells (p=n.s.).	idarubicinol	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
11977108-5	2002	Tissue distribution also differed: idarubicin and idarubicinol concentrations were lower in heart, lung, spleen, and kidneys after IDA-SLN administration than after solution administration.	idarubicinol	50-62	sarcolipin	Rattus norvegicus	135-138
10374847-9	1999	IDAol was at least 32-fold more cytotoxic than DOXol, and more susceptible to Pgp transport than IDA.	idarubicinol	0-5	ATP binding cassette subfamily B member 1	Homo sapiens	78-81
8995514-2	1996	IDA is converted in the liver into idarubicinol (2HIDA) and, in this form, seems to exert its antitumoral activity in vivo.	idarubicinol	35-47	alpha-L-iduronidase	Homo sapiens	0-3